ABSTRACT
This study is an attempt to elucidate of agmatine effects upon leukocyte apoptosis in experimental diabetes mellitus (EDM). We demonstrated the increase in numbers of the leukocytes with both early and late signs of apoptosis at diabetes. Further changes in the morphofunctional state of the leukocytes include the increased amount of fragmented DNA, elevated apoptotic index and violated ratio of p53 to Bcl-2 proteins. Agmatine has been shown to exert direct corrective effects on leukocyte apoptosis: the content of Ñ53 and Bcl-2 proteins was normalized, apoptotic index was decreased, the process of nuclear DNA degradation was ceased, while the amount of cells with early and late signs of apoptosis was diminished.
Subject(s)
Agmatine/pharmacology , Apoptosis/drug effects , Diabetes Mellitus, Experimental/drug therapy , Hypoglycemic Agents/pharmacology , Animals , Apoptosis/genetics , DNA Fragmentation/drug effects , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Gene Expression Regulation , Leukocytes/drug effects , Leukocytes/metabolism , Leukocytes/pathology , Male , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Signal Transduction , Streptozocin , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolismABSTRACT
This paper reports the results of a study of the impact of the agmatine treatment on erythrocyte resistance to acid hemolytic, reticulocyte count and reticulocyte production index, erythrocyte surface architectonics in streptozotocin-induced diabetic rats. Our results indicate that treatment of diabetic rats with agmatine causes a suppression of erythropoiesis and increases the resistance of erythrocytes against HCl-induced hemolysis. It was shown a 10% increase in the number of young red blood cells and 35% reduction in the number of structurally transformed erythrocytes that are capable of restoring normal biconcave disc shape under physiological condition. Our data demonstrate an improvement of morphofunctional state of red blood cells in diabetes and reflect the positive effect of agmatine treatment on erythrone due to the glucose-lowering action.
Subject(s)
Agmatine/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Erythrocytes/drug effects , Erythroid Precursor Cells/drug effects , Erythropoiesis/drug effects , Agmatine/administration & dosage , Animals , Blood Glucose/analysis , Decarboxylation , Diabetes Mellitus, Experimental/blood , Erythrocyte Count , Erythrocytes/physiology , Erythroid Precursor Cells/physiology , Male , Rats , StreptozocinABSTRACT
The effects of agmatine on oxidative and nonoxidative metabolic pathways of L-arginine were investigated both in plasma and erythrocytes under experimental diabetes mellitus. It was indicated, that agmatine prevents the development of oxidative-nitrosative stress in diabetic rats. After treatment of animals by agmatine NO-synthase methabolic pathway of L-arginine is depressed whereas arginase one increases in erythrocytes of rats with experimental diabetes mellitus.
